Dr. Simon Turcotte

Dr. Turcotte is a prominent Canadian surgeon-scientist specializing in solid cancer immunology and cellular immunotherapy. Holding prestigious research chairs and awards, including the Roger des Groseillers Research Chair at the Université de Montréal and an Innovator Award from the Canadian Association of Surgeons, his expertise is well-recognized throughout North America. Dr. Turcotte's groundbreaking work has revealed the existence of T-cell responses against chemotherapy-resistant metastatic GI cancers, leading to the isolation of T-cell clones with tumor recognition. He has also played a pivotal role in developing immunogenomic methods for identifying neoantigen-reactive T-cells, which have shown promise in clinical responses for GI cancer patients.

Dr. Turcotte also leads a translational research program with a focus on T-cell immunotherapies for hepatopancreatobiliary (HPB) malignancies and manages a substantial HPB cancer biobank. Lastly, Dr. Turcotte oversees the T cell immunotherapy program at the Centre hospitalier de l'université de Montréal (CHUM), where they have initiated groundbreaking trials in metastatic melanoma and gene-engineered T-cell therapies, and hope to do the same for the Canadian Cholangiocarcinoma Collaborative